Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01945047

Action of Ketamine in Treatment-Resistant Depression

Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Treatment-resistant Depression

Interventions Ketamine Midazolam

Updated 6 times since 2017 Last updated: Jun 22, 2018 Started: May 31, 2013 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Treatment-resistant Depression and is currently completed. Canadian Institutes of Health Research (CIHR) leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jul 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2_PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Institutes of Health Research (CIHR)
University of Ottawa

Data source: University of Ottawa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ottawa, Canada